N-propyl-2,3-dihydro-1H-indene-2-carboxamide | 1313588-39-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: N-propyl-2,3-dihydro-1H-indene-2-carboxamide
• CAS: 1313588-39-4
• 化学式: C₁₃H₁₇NO
• 分子量: 203.284
• InChiKey: IBPFHMBIICBYIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-propyl-2,3-dihydro-1H-indene-2-carboxamide 在 劳森试剂 、 mercury(II) diacetate 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 3-(2,3-dihydro-1H-inden-2-yl)-4-propyl-1,2,4-triazole
  参考文献：
  名称：

  Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors

  摘要：

  Previous efforts have led to the identification of a potent, selective, and nonphlorizin based SGLT2 inhibitor 1. This Letter describes efforts to further optimize the potency, microsomal stability, solubility and pharmacokinetic properties of this series of SGLT2 inhibitors. From these efforts, compounds 28 and 32 have improved solubility and pharmacokinetic properties compared to compound 1 (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.053
• 作为产物：
  描述：

  正丙胺 、 2-茚羧酸 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 以80%的产率得到N-propyl-2,3-dihydro-1H-indene-2-carboxamide
  参考文献：
  名称：

  Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors

  摘要：

  Previous efforts have led to the identification of a potent, selective, and nonphlorizin based SGLT2 inhibitor 1. This Letter describes efforts to further optimize the potency, microsomal stability, solubility and pharmacokinetic properties of this series of SGLT2 inhibitors. From these efforts, compounds 28 and 32 have improved solubility and pharmacokinetic properties compared to compound 1 (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.053

文献信息

• QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS
  申请人：Collingwood Stephen Paul

  公开号：US20100041887A1

  公开（公告）日：2010-02-18

  Compounds of formula I in salt or zwitterionic form wherein, wherein R 1 , R 2 , R 3 , and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  具有式I的化合物，其以盐或双离子形式存在，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由肌肉乙酰胆碱M3受体介导的疾病。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。
• Quinuclidine derivatives binding to mucarinic m3 receptors
  申请人：Collingwood Paul Stephen

  公开号：US20070060563A1

  公开（公告）日：2007-03-15

  Compounds of formula I in salt or zwitterionic form wherein, wherein R 1 , R 2 , R 3 , and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  具有式I的盐或双电离形式的化合物，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由肌肉型M3受体介导的病症。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。
• US8168654B2
  申请人：——

  公开号：US8168654B2

  公开（公告）日：2012-05-01
• Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors
  作者：Xiaohui Du、Mike Lizarzaburu、Simon Turcotte、Taeweon Lee、Joanne Greenberg、Bei Shan、Peter Fan、Yun Ling、Julio C. Medina、Jonathan Houze

  DOI：10.1016/j.bmcl.2011.04.053

  日期：2011.6

  Previous efforts have led to the identification of a potent, selective, and nonphlorizin based SGLT2 inhibitor 1. This Letter describes efforts to further optimize the potency, microsomal stability, solubility and pharmacokinetic properties of this series of SGLT2 inhibitors. From these efforts, compounds 28 and 32 have improved solubility and pharmacokinetic properties compared to compound 1 (C) 2011 Elsevier Ltd. All rights reserved.